We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

49 hedge funds and large institutions have $1.89M invested in BioXcel Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 27 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.15% less ownership

Funds ownership: 1.63% → 0.48% (-1.2%)

34% less funds holding

Funds holding: 74 → 49 (-25)

35% less call options, than puts

Call options by funds: $22K | Put options by funds: $34K

74% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 27

85% less capital invested

Capital invested by funds: $12.5M → $1.89M (-$10.6M)

86% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 29

Holders
49
Holders Change
-25
Holders Change %
-33.78%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
27
Closed
29
Calls
$22K
Puts
$34K
Net Calls
-$12K
Net Calls Change
+$175K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$194K
2
Renaissance Technologies
Renaissance Technologies
New York
+$109K
3
Wells Fargo
Wells Fargo
California
+$43.1K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$26.3K
5
Group One Trading
Group One Trading
Illinois
+$25.3K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$3.82M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.82M
3
Charles Schwab
Charles Schwab
California
-$261K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$192K
5
Northern Trust
Northern Trust
Illinois
-$130K
Name Holding Trade Value Shares
Change 		Change in
Stake
SWM
26
SeaCrest Wealth Management
New York
$7.53K -$2.85K -212 -22%
TAM
27
Tocqueville Asset Management
New York
$7.26K -$26.7K -1,990 -73%
TRCT
28
Tower Research Capital (TRC)
New York
$6.71K -$914 -68 -9%
Truist Financial
29
Truist Financial
North Carolina
$6.64K – – –
XT
30
XTX Topco
Cayman Islands
$6.53K -$30.1K -2,237 -77%
AWM
31
Apollon Wealth Management
South Carolina
$6.2K -$202 -15 -2%
Osaic Holdings
32
Osaic Holdings
Arizona
$5.18K +$3.25K +242 +84%
Zurich Cantonal Bank
33
Zurich Cantonal Bank
Switzerland
$3.68K -$457 -34 -8%
CFM
34
Catalyst Funds Management
Australia
$3.17K – – –
Federated Hermes
35
Federated Hermes
Pennsylvania
$2.94K -$38.2K -2,840 -90%
AWM
36
AllSquare Wealth Management
New York
$2.76K – – –
WTA
37
Washington Trust Advisors
Massachusetts
$1.57K – – –
National Bank of Canada
38
National Bank of Canada
Quebec, Canada
$1.45K -$202 -15 -9%
PFBT
39
Parkside Financial Bank & Trust
Missouri
$1.1K +$1.52K +113 New
Simplex Trading
40
Simplex Trading
Illinois
$1K -$24.5K -1,823 -90%
JP Morgan Chase
41
JP Morgan Chase
New York
$457 – – –
NA
42
NewEdge Advisors
Louisiana
$305 – – –
TFA
43
Toth Financial Advisory
Virginia
$305 – – –
Northwestern Mutual Wealth Management
44
Northwestern Mutual Wealth Management
Wisconsin
$207 -$13 -1 -5%
FDCDDQ
45
Federation des caisses Desjardins du Quebec
Quebec, Canada
$69 – – –
Barclays
46
Barclays
United Kingdom
$54 -$40 -3 -33%
PD
47
Point72 (DIFC)
United Arab Emirates
$19 -$12.9K -961 -100%
Citigroup
48
Citigroup
New York
$2 -$46.8K -3,486 Closed
AC
49
Armistice Capital
New York
– -$3.82M -186,688 Closed
Fidelity Investments
50
Fidelity Investments
Massachusetts
– -$2.82M -137,823 Closed
1
2
3 4

BTAI Hedge Fund Activity: Q3 2024 in Review

49 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2024, worth a combined $1.89M — down 85% from $12.5M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of BTAI and 4 opened new positions — a net loss of 25 holders — while 27 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $194K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.82M sold.

  • 49 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2024, down from 74 in Q2 2024.
  • Funds reported $1.89M of BioXcel Therapeutics stock for Q3 2024, down 85% quarter-over-quarter.
  • 4 funds opened new BioXcel Therapeutics positions in Q3 2024 and 29 closed out, a net change of -25 holders.
  • The largest BioXcel Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $194K added.
  • The largest BioXcel Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $3.82M sold.

Based on aggregated 13F filings for Q3 2024.